Join Us in Solving Pandemic-Sized Problems

Investor Overview

Pardes is a clinical-stage biopharmaceutical company created by and for this moment to solve pandemic-sized problems, starting with COVID-19. We are applying modern reversible-covalent chemistry as a starting point to develop novel drugs while reimagining the patient journey to access these medicines.

Learn More

Stock
Quote

Volume:

03/07/2023 8:51 AMEST

Press
Releases

03/14/2023

Pardes Biosciences Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

02/01/2023

Pardes Biosciences to Present at SVB Securities Global Biopharma Conference

11/07/2022

Pardes Biosciences Reports Third Quarter 2022 Financial Results and Provides Business Update

11/01/2022

Pardes Biosciences to Present at Jefferies London Healthcare Conference

Webcasts

Financial Information

Document Date	Description	Form	View
06/29/2021	Filing of certain prospectuses and communications in connection with business combination transactions	425	View HTML 0001213900-21-034553.pdf 0001213900-21-034553.rtf 0001213900-21-034553.xls
07/09/2021	Filing of certain prospectuses and communications in connection with business combination transactions	425	View HTML 0001213900-21-036257.pdf 0001213900-21-036257.rtf
07/09/2021	Filing of certain prospectuses and communications in connection with business combination transactions	425	View HTML 0001213900-21-036367.pdf 0001213900-21-036367.rtf 0001213900-21-036367.xls
08/05/2021	Filing of certain prospectuses and communications in connection with business combination transactions	425	View HTML 0001213900-21-040397.pdf 0001213900-21-040397.rtf
08/26/2021	Filing of certain prospectuses and communications in connection with business combination transactions	425	View HTML 0001213900-21-044900.pdf 0001213900-21-044900.rtf
08/26/2021	Filing of certain prospectuses and communications in connection with business combination transactions	425	View HTML 0001213900-21-044984.pdf 0001213900-21-044984.rtf
08/27/2021	Filing of certain prospectuses and communications in connection with business combination transactions	425	View HTML 0001213900-21-045161.pdf 0001213900-21-045161.rtf
09/01/2021	Filing of certain prospectuses and communications in connection with business combination transactions	425	View HTML 0001213900-21-046132.pdf 0001213900-21-046132.rtf 0001213900-21-046132.xls
09/21/2021	Filing of certain prospectuses and communications in connection with business combination transactions	425	View HTML 0001213900-21-049099.pdf 0001213900-21-049099.rtf
10/06/2021	Filing of certain prospectuses and communications in connection with business combination transactions	425	View HTML 0001213900-21-051502.pdf 0001213900-21-051502.rtf

Contact
IR

Send us an investor-related question using the form below.